Cargando…
Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC
OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidru...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751228/ https://www.ncbi.nlm.nih.gov/pubmed/35705368 http://dx.doi.org/10.1136/gutjnl-2021-326500 |
_version_ | 1784850426587250688 |
---|---|
author | Awoniyi, Muyiwa Wang, Jeremy Ngo, Billy Meadows, Vik Tam, Jason Viswanathan, Amba Lai, Yunjia Montgomery, Stephanie Farmer, Morgan Kummen, Martin Thingholm, Louise Schramm, Christoph Bang, Corinna Franke, Andre Lu, Kun Zhou, Huiping Bajaj, Jasmohan S Hylemon, Phillip B Ting, Jenny Popov, Yury V Hov, Johannes Roksund Francis, Heather L Sartor, Ryan Balfour |
author_facet | Awoniyi, Muyiwa Wang, Jeremy Ngo, Billy Meadows, Vik Tam, Jason Viswanathan, Amba Lai, Yunjia Montgomery, Stephanie Farmer, Morgan Kummen, Martin Thingholm, Louise Schramm, Christoph Bang, Corinna Franke, Andre Lu, Kun Zhou, Huiping Bajaj, Jasmohan S Hylemon, Phillip B Ting, Jenny Popov, Yury V Hov, Johannes Roksund Francis, Heather L Sartor, Ryan Balfour |
author_sort | Awoniyi, Muyiwa |
collection | PubMed |
description | OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidrug-resistant 2 deficient (mdr2(−/−) ) mice and microbial profiles in PSC patient cohorts. DESIGN: We measured weights, liver enzymes, RNA expression, histological, immunohistochemical and fibrotic biochemical parameters, faecal 16S rRNA gene profiling and metabolomic endpoints in gnotobiotic and antibiotic-treated SPF mdr2(−/−) mice and targeted metagenomic analysis in PSC patients. RESULTS: GF mdr2(−/−) mice had 100% mortality by 8 weeks with increasing hepatic bile acid (BA) accumulation and cholestasis. Early SPF autologous stool transplantation rescued liver-related mortality. Inhibition of ileal BA transport attenuated antibiotic-accelerated liver disease and decreased total serum and hepatic BAs. Depletion of vancomycin-sensitive microbiota exaggerated hepatobiliary disease. Vancomycin selectively decreased Lachnospiraceae and short-chain fatty acids (SCFAs) but expanded Enterococcus and Enterobacteriaceae. Antibiotics increased Enterococcus faecalis and Escherichia coli liver translocation. Colonisation of GF mdr2(−/−) mice with translocated E. faecalis and E. coli strains accelerated hepatobiliary inflammation and mortality. Lachnospiraceae colonisation of antibiotic pretreated mdr2(−/−) mice reduced liver fibrosis, inflammation and translocation of pathobionts, and SCFA-producing Lachnospiraceae and purified SCFA decreased fibrosis. Faecal Lachnospiraceae negatively associated, and E. faecalis/ Enterobacteriaceae positively associated, with PSC patients’ clinical severity by Mayo risk scores. CONCLUSIONS: We identified novel functionally protective and detrimental resident bacterial species in mdr2(−/−) mice and PSC patients with associated clinical risk score. These insights may guide personalised targeted therapeutic interventions in PSC patients. |
format | Online Article Text |
id | pubmed-9751228 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97512282023-04-01 Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC Awoniyi, Muyiwa Wang, Jeremy Ngo, Billy Meadows, Vik Tam, Jason Viswanathan, Amba Lai, Yunjia Montgomery, Stephanie Farmer, Morgan Kummen, Martin Thingholm, Louise Schramm, Christoph Bang, Corinna Franke, Andre Lu, Kun Zhou, Huiping Bajaj, Jasmohan S Hylemon, Phillip B Ting, Jenny Popov, Yury V Hov, Johannes Roksund Francis, Heather L Sartor, Ryan Balfour Gut Gut Microbiota OBJECTIVE: Conflicting microbiota data exist for primary sclerosing cholangitis (PSC) and experimental models. Goal: define the function of complex resident microbes and their association relevant to PSC patients by studying germ-free (GF) and antibiotic-treated specific pathogen-free (SPF) multidrug-resistant 2 deficient (mdr2(−/−) ) mice and microbial profiles in PSC patient cohorts. DESIGN: We measured weights, liver enzymes, RNA expression, histological, immunohistochemical and fibrotic biochemical parameters, faecal 16S rRNA gene profiling and metabolomic endpoints in gnotobiotic and antibiotic-treated SPF mdr2(−/−) mice and targeted metagenomic analysis in PSC patients. RESULTS: GF mdr2(−/−) mice had 100% mortality by 8 weeks with increasing hepatic bile acid (BA) accumulation and cholestasis. Early SPF autologous stool transplantation rescued liver-related mortality. Inhibition of ileal BA transport attenuated antibiotic-accelerated liver disease and decreased total serum and hepatic BAs. Depletion of vancomycin-sensitive microbiota exaggerated hepatobiliary disease. Vancomycin selectively decreased Lachnospiraceae and short-chain fatty acids (SCFAs) but expanded Enterococcus and Enterobacteriaceae. Antibiotics increased Enterococcus faecalis and Escherichia coli liver translocation. Colonisation of GF mdr2(−/−) mice with translocated E. faecalis and E. coli strains accelerated hepatobiliary inflammation and mortality. Lachnospiraceae colonisation of antibiotic pretreated mdr2(−/−) mice reduced liver fibrosis, inflammation and translocation of pathobionts, and SCFA-producing Lachnospiraceae and purified SCFA decreased fibrosis. Faecal Lachnospiraceae negatively associated, and E. faecalis/ Enterobacteriaceae positively associated, with PSC patients’ clinical severity by Mayo risk scores. CONCLUSIONS: We identified novel functionally protective and detrimental resident bacterial species in mdr2(−/−) mice and PSC patients with associated clinical risk score. These insights may guide personalised targeted therapeutic interventions in PSC patients. BMJ Publishing Group 2023-04 2022-06-15 /pmc/articles/PMC9751228/ /pubmed/35705368 http://dx.doi.org/10.1136/gutjnl-2021-326500 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Gut Microbiota Awoniyi, Muyiwa Wang, Jeremy Ngo, Billy Meadows, Vik Tam, Jason Viswanathan, Amba Lai, Yunjia Montgomery, Stephanie Farmer, Morgan Kummen, Martin Thingholm, Louise Schramm, Christoph Bang, Corinna Franke, Andre Lu, Kun Zhou, Huiping Bajaj, Jasmohan S Hylemon, Phillip B Ting, Jenny Popov, Yury V Hov, Johannes Roksund Francis, Heather L Sartor, Ryan Balfour Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title | Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title_full | Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title_fullStr | Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title_full_unstemmed | Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title_short | Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC |
title_sort | protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of psc |
topic | Gut Microbiota |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9751228/ https://www.ncbi.nlm.nih.gov/pubmed/35705368 http://dx.doi.org/10.1136/gutjnl-2021-326500 |
work_keys_str_mv | AT awoniyimuyiwa protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT wangjeremy protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT ngobilly protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT meadowsvik protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT tamjason protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT viswanathanamba protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT laiyunjia protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT montgomerystephanie protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT farmermorgan protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT kummenmartin protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT thingholmlouise protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT schrammchristoph protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT bangcorinna protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT frankeandre protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT lukun protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT zhouhuiping protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT bajajjasmohans protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT hylemonphillipb protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT tingjenny protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT popovyuryv protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT hovjohannesroksund protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT francisheatherl protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc AT sartorryanbalfour protectiveandaggressivebacterialsubsetsandmetabolitesmodifyhepatobiliaryinflammationandfibrosisinamurinemodelofpsc |